KA - Kineta Inc
IEX Last Trade
0.642
0.001 0.093%
Share volume: 91,132
Last Updated: Fri 30 Aug 2024 06:21:42 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.64
0.00
0.09%
Fundamental analysis
29%
Profitability
43%
Dept financing
19%
Liquidity
34%
Performance
18%
Performance
5 Days
1.59%
1 Month
4.75%
3 Months
34.74%
6 Months
-71.68%
1 Year
-67.18%
2 Year
113.83%
Key data
Stock price
$0.64
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.33 - $5.39
52 WEEK CHANGE
-$0.68
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Meenu Chhabra
Region: US
Website: http://www.proteostasis.com/
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.proteostasis.com/
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
proteostasis therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or proteostasis network. the proteostasis network maintains the body’s natural balance of proteins to protect us from numerous diseases. these novel therapies, or proteostasis regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the proteostasis network, such as alzheimer’s disease, emphysema, huntington’s disease, and type ii diabetes.
Recent news